Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Chief Scientific Officer | April 01, 2025 | April 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date April 01, 2025 · Filed April 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.86 · Expires 2035-03-31 | Direct | 45,000 |
Reported balance
After 2025-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-01 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2025 Filed Apr 3, 2025 16:09 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001628280-25-016486 · wk-form4_1743710973.xml · derivative · entry 1 Bumcrot David · CIK 0002033326 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.